Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)

TPE:6919 Revenue

Caliway Biopharmaceuticals had revenue of 3.57M TWD in the quarter ending June 30, 2026, a decrease of -70.80%. This brings the company's total for the last twelve months to 29.39M, down -34.44% year-over-year. In the year 2025, Caliway Biopharmaceuticals had annual revenue of 38.04M, down -14.40%. That makes Caliway Biopharmaceuticals the 43,737th largest company in the world by revenue and 2,165th in Taiwan.

• Revenue (ttm): 29.39M
• Revenue Growth: -34.44%
• P/S Ratio: 3,905.30
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 114.79B

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	38.04M	-6.40M	-14.40%
Dec 31, 2024	44.43M	5.50M	14.13%
Dec 31, 2023	38.93M	26.11M	203.68%
Dec 31, 2022	12.82M	481.00K	3.90%
Dec 31, 2021	12.34M	1.99M	19.22%

Data Source: S&P Global Market Intelligence Last updated: Aug 11, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 19, 2026

Data Sources Report a data error